Yasser Ged

36 Clear Cell Renal Cell Carcinoma Consensus Transcriptomic Programs Reveal Converging Trajectories Towards Aggressive Disease

Abstract Background Clear cell renal cell carcinoma (ccRCC) is characterized by a branching genomic architecture in which biallelic VHL inactivation is followed by divergence into PBRM1- or BAP1-mutant lineages, with subsequent acquisition of additional alterations contributing to progression and aggressive behavior. H...

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...

Spatial distribution and prognostic significance of hemorrhagic imaging features in brain metastases from metastatic renal cell carcinoma

59 GPNMB:CD44 Signaling Drives Tumor Progression in Translocation Renal Cell Carcinoma

Abstract Background MiT/TFE-rearranged, translocation renal cell carcinoma (tRCC) is characterized by gene fusions involving TFE3 or TFEB, and is a rare, aggressive non-ccRCC, often occurring in children and with few biomarkers or targeted therapy options. TFE3 is the most commonly translocated gene with ASPSCR1, PRCC...